anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Controlled trials with Isosorbide Mononitrate Extended-Release Tablets have demonstrated antianginal activity following acute and chronic dosing. Administration of Isosorbide Mononitrate Extended-Release Tablets once daily, taken early in the morning on arising, provided at least 12 hours of antianginal activity.

In a placebo-controlled parallel study, 30, 60, 120 and 240 mg of Isosorbide Mononitrate Extended-Release Tablets were administered once daily for up to 6 weeks. Prior to randomization, all patients completed a 1- to 3-week single-blind placebo phase to demonstrate nitrate responsiveness and total exercise treadmill time reproducibility. Exercise tolerance tests using the Bruce Protocol were conducted prior to and at 4 and 12 hours after the morning dose on days 1, 7, 14, 28 and 42 of the double-blind period. Isosorbide Mononitrate Extended-Release Tablets 30 and 60 mg (only doses evaluated acutely) demonstrated a significant increase from baseline in total treadmill time relative to placebo at 4 and 12 hours after the administration of the first dose. At day 42, the 120 and 240 mg dose of Isosorbide Mononitrate Extended-Release Tablets demonstrated a significant increase in total treadmill time at 4 and 12 hours post dosing, but by day 42, the 30 and 60 mg doses no longer were differentiable from placebo. Throughout chronic dosing, rebound was not observed in any isosorbide mononitrate extended-release treatment group.

Pooled data from two other trials, comparing Isosorbide Mononitrate Extended-Release Tablets 60 mg once daily, ISDN 30 mg QID, and placebo QID in patients with chronic stable angina using a randomized, double-blind, three-way crossover design found statistically significant increases in exercise tolerance times for Isosorbide Mononitrate Extended-Release Tablets compared to placebo at hours 4, 8 and 12 and to ISDN at hour 4. The increases in exercise tolerance on day 14, although statistically significant compared to placebo, were about half of that seen on day 1 of the trial.
During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a method for temporary hemorrhage control used in haemodynamically unwell patients with severe bleeding. In haemodynamically unwell abdominal trauma patients, laparotomy remains the initial procedure of choice. Using REBOA in patients as a bridge to laparotomy is a novel option whose feasibility and efficacy remain unclear. We aimed to assess the clinical outcome in patients with abdominal injury who underwent both REBOA placement and laparotomy.
METHODS: This is a retrospective study, including trauma patients with an isolated abdominal injury who underwent both REBOA placement and laparotomy, during the period 2011-2019. All data were collected via the Aortic Balloon Occlusion Trauma Registry database.
RESULTS: One hundred and three patients were included in this study. The main mechanism of trauma was blunt injury (62.1%) and the median injury severity score (ISS) was 33 (14-74). Renal failure and multi-organ dysfunction syndrome (MODS) occurred in 15.5% and 35% of patients, respectively. Overall, 30-day mortality was 50.5%. Post balloon inflation systolic blood pressure (SBP) >80 mmHg was associated with lower 24-h mortality (p = 0.007). No differences in mortality were found among patients who underwent partial occlusion vs. total occlusion of the aorta.
CONCLUSIONS: Our results support the feasibility of REBOA use in patients with isolated abdominal injury, with survival rates similar to previous reports for haemodynamically unstable abdominal trauma patients. Post-balloon inflation SBP >80 mmHg was associated with a significant reduction in 24-h mortality rates, but not 30-day mortality. Total aortic occlusion was not associated with increased mortality, MODS, and complication rates compared with partial occlusion.
The present invention provides anisodamine frostbite ointment for treating frostbite and scleredema and a preparation method thereof, which relates to a medicine preparation containing organic effective components. The present invention aims at providing ointment prepared from anisodamine for treating frostbite and neonate scleredema in a short time and a preparation method thereof. The anisodamine frostbite ointment is characterized in that the ointment comprises the components by weight ratios: 15 to 20% of anisodamine, 5 to 15% of chlorpheniramine and balance of medicinal vaseline; auxiliary materials comprise one kind of 0.2 to 0.4% of metronidazole and 5 to 15% of prednisone or the combination of metronidazole and prednisone, and also comprise an amount of vitamin E. The preparation method comprises: after the medicinal vaseline is heated, the anisodamine and the auxiliary materials are added to the heated medicinal vaseline according to the proportion and are uniformly mixed; after being cooled, the mixture is put into a box. The components of the ointment can be purchased on market, and the preparation method is simple. The ointment has the advantages of low treatment expense for patients, convenient use and obvious effects. The externally-applied ointment can protect skin in cold and dry weather.
The invention discloses a non-small cell lung cancer pathogenic gene and application thereof. A non-small cell lung cancer pathogenic gene, the sequence of which is shown in SEQ ID NO. 1. The specific antisense oligonucleotide is utilized to down regulate the expression of CTD-2245E15.3, and the growth of lung cancer cells can be obviously inhibited in vitro and in vivo. By constructing an in-situ lung cancer model and observing the in-vivo cancer promotion effect of lncRNA, experiments show that the over-expression of CTD-2245E15.3 obviously increases the lung tumor load. CTD-2245E15.3 plays an important role as a proto-oncogene lncRNA in anabolic processes. Therefore, CTD-2245E15.3 can be used as a therapeutic target to be applied to preparation and screening of medicaments for treating NSCLC. Substances capable of inhibiting CTD-2245E15.3 or down-regulating CTD-2245E15.3 expression can also be used for preparing medicaments for treating NSCLC.
This prospective study was performed among patients diagnosed - by the doctors acting as the expert panel of this study - with OA of the lower limb. The recruitment period was: June 2017 and November 2017, in six hospitals situated in six different geographical regions of Hungary. The participating hospitals were selected in a way to represent different geographic and cultural areas of the country; the patients were selected randomly by the doctors of the given sites. The process was conducted with the contribution of: (1) Translation committee (4 members), (2) Our research team, as moderator (4 members), (3) Expert panel (6 doctors professors of the study sites: orthopaedists, rheumatologists, musculoskeletal rehabilitation doctors). The used instruments were for the validation process: Short version of World Health Organization Quality of life questionnaire (WHOQoL-BREF), EuroQuality of Life - 5-dimension questionnaire as generic quality of life measurement tools (EQ-5D - VAS). In addiction 99 patients filled the questionnaires in an appropriate way. The results were evaluated by 23.0 version of SPSS program.
PURPOSE:To provide a composition containing S-adenosyl-L-methionine (abbreviated as SAM) in a state having improved absorbability and bioavailability, and useful as a remedy for jecur adiposum, hyperlipemia, arteriosclerosis, etc., by compounding SAM with a monocarboxylic acid. CONSTITUTION:The titled composition can be prepared by compounding an SAM salt with a monocarboylic acid of formula RCOOH or its salt. The SAM salt is a salt consisting of 1pt. of SAM and 0.5-3pts., preferably 2-3pts. of an acid (e.g. hydrobromic acid, hydrochloric acid, hydroiodic acid, etc.). The monocarboxylic acid is preferably the one having 1-7C alkyl, alkenyl, etc. as the R group, and is, e.g. acetic acid, butyric acid, lactic acid, sorbic acid, etc. The molar ratio of the SAM salt to the monocarboxylic acid is preferably 1:1-4. The compounding of the fatty acid to SAM increases the absorbability of SAM through the intestines, improves the bioavailability, and gives a composition suitable as a drug such as powder, tablet, etc.
The most challenging problems in karyotyping are segmentation and classification of overlapping chromosomes in metaphase spread images. Often chromosomes are bent in different directions with varying degrees of bend. Tediousness and time consuming nature of the effort for ground truth creation makes it difficult to scale the ground truth for training phase. The present disclosure provides an end-to-end solution that reduces the cognitive burden of segmenting and karyotyping chromosomes. Dependency on experts is reduced by employing crowdsourcing while simultaneously addressing the issues associated with crowdsourcing. Identified segments through crowdsourcing are pre-processed to improve classification achieved by employing deep convolutional network (CNN).
HIV protease inhibitors are among the most powerful drugs in suppressing HIV in human patients. However, HIV developed resistance to all protease inhibitor drugs so far marketed or used in clinical trials. HIV generates resistance by mutating its protease. The strains of HIV containing mutant proteases less vulnerable to inhibitor drug are able to replicate better and maintain the infection. No effective principle exists for the design of resistance-proof HIV protease inhibitors (HIVPr). A new inhibitor has been developed based on a new concept for designing resistance invulnerable HIVPr inhibitors. In vitro data have shown that this inhibitor is effective against many known HIVPr mutants resistant to other HIVPr inhibitor drugs. The new concept is, therefore, generally applicable for the design of other resistance invulnerable HIVPr inhibitor drugs.
Treatment with KADCYLA has not been studied in patients who had trastuzumab permanently discontinued due to infusion-related reactions (IRRs) and/or hypersensitivity; treatment with KADCYLA is not recommended for these patients.

Infusion-related reactions, characterized by one or more of the following symptoms − flushing, chills, pyrexia, dyspnea, hypotension, wheezing, bronchospasm, and tachycardia have been reported in clinical trials of KADCYLA. In EMILIA, the overall incidence of IRRs in patients treated with KADCYLA was 1.4%. In KATHERINE, the overall incidence of IRRs in patients treated with KADCYLA was 1.6% [see Adverse Reactions (6.1)]. In most patients, these reactions resolved over the course of several hours to a day after the infusion was terminated. KADCYLA treatment should be interrupted in patients with severe IRR. KADCYLA treatment should be permanently discontinued in the event of a life-threatening IRR [see Dosage and Administration (2.2)]. Patients should be observed closely for IRR reactions, especially during the first infusion. 

One case of a serious, allergic/anaphylactic-like reaction has been observed in clinical trials of single-agent KADCYLA. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use.
This study intends to select first-year undergraduate nursing students registered in October 2024 at Changzhi Medical College in Shanxi as the sampling population. A total of 120 eligible individual samples in eligible clusters will be screened according to inclusion and exclusion criteria, and the cluster samples will be randomly assigned to either the wait-list group or the intervention group. Participants in wait-list group will not receive any intervention, while participants in intervention group will receive IMB-based stress self-management health education. The intervention will last for 8 weeks, with one module delivers by weeks. Each module will include a 30-40 minute lecture combined with exercises, discussions, and role-playing activities. Measurements will be taken before the intervention, immediately after the intervention, and at 1 month, 3 months, and 6 months post-intervention. These measurements will include the Stress Knowledge Questionnaire, the Multidimensional Scale of Perceived Social Support, the Self-Compassion Scale, the Resilience Scale, and the stress sub-scale of the Depression Anxiety Stress Scale.

The study data will be analyzed using the intention-to-treat (ITT) method. Continuous data will be described using mean (standard deviation) or median (interquartile range), and categorical data will be described using frequency and percentage. Repeated measures ANOVA will be used to compare differences between the two groups before the intervention, immediately after the intervention, and at 1 month, 3 months, and 6 months post-intervention. Generalized linear models (GMM) will be utilized to determine the effects of IMB-based stress self-management health education on the variables immediately post-intervention, and at 1 month, 3 months, and 6 months post-intervention, while controlling for confounding variables. Sensitivity analysis will be performed and reported. The mean estimates will be set with a 95% confidence interval, and the significance level will be set at P \< 0.05.

This study aims to explore new low-cost approaches for current college student mental health education, improve stress self-management abilities and stress levels among nursing students, prevent mental disorders, and promote mental health. To ensure the safety of participants throughout the study, the research team will strictly adhere to ethical standards and undergo review and supervision by the ethics committee. Informed consent will be obtained from participants, and their privacy and personal information will be kept confidential, not disclosed or misused. Regular safety monitoring and risk assessments will be conducted. The research protocol will be strictly followed, and psychological counseling services will be provided to participants.
Group T were given propofol infusions of 12 mg/kg/hr for the first 10 minutes, 9 mg/kg/hr for the second 10 minutes and 6 mg/kg/hr after that. Patients were ventilated with 50% air and 50% O2 mix at 6 L/min flow.
Monitoring the progression of a wound is critical, as it involves repeated clinical trips and lab tests over days. An artificial intelligence (AI) based system and method for analyzing wounds on a person is provided. The system is configured to take an image of the wound taken from a camera of a person. This image is then provided to the physician after the analysis and physician is able to provide a feedback to the person in terms of a healing index. In the analysis part, the system provides a fully automatized wound segmentation and quantify the parameters that assist wound care professionals. An Al based estimation module is provided, implemented with morphological operations, connected component analysis, and shape analysis, improving accuracy and providing the wound parameter and metrics such as area, perimeter, circle diameter, major and minor axis length of an ellipse.
Hypergranulation tissue surrounding gastrostomy tube sites in pediatric patients is a significant problem. This tissue may cause drainage or bleeding that bothers patients and parents. Numerous methods of treatment are used for treatment of hypergranulation tissue, but no data exists to support one method of treatment over another. The investigators plan to perform a prospective randomized trial of three different therapies (silver nitrate cauterization, topical kenalog, and soap cloth abrasion) to identify the best treatment modality. Participants will be followed via office visit at four and eight weeks after initiation of therapy. Measurements of the granulation tissue and photographs will be obtained pre treatment and at each post treatment visit. In addition parents will be asked to fill out a pre and post treatment survey regarding improvement in symptoms. Investigators plan to enroll 120 patients total with the intention of having 40 participants in each group.
The invention provides a benzamide derivant. A chemical method is utilized to combine a series of benzoate derivants including ester compounds, (sulfur) ether compounds and amide compounds. Most combined compounds have new chemical structure. An external cell viability experiment verifies that the combined benzoate derivant has remarkable viability similar to nerve growth factor (NGF). An internal animal experiment verfies that the combined new compound 2,3- dihydroxy-benzoic acid-14 ester has the effect of strengthening memory of aged mouse. Therefore, the benzoate derivant can be applied in preparation of medicine for preventing and treating neurodegenerative diseases like senile dementia, particularly being applied to preparation of medicine for treating Alzheimer's disease (AD) and other neurodegenerative diseases. By means of the method, new medicine use of the benzoate derivant is developed. The preparation method is reasonable and convenient to operate. The benzamide derivant provides new medicines for treatment of neurodegenerative diseases like senile dementia.
Reproduction studies have been performed in mice and rats with intravenous daily doses of 15 mg/kg, and in rabbits with 7.5 mg/kg. These doses are 0.42 and 0.14 times the daily oral human doses of ELMIRON ®when normalized to body surface area. These studies did not reveal evidence of impaired fertility or harm to the fetus from ELMIRON ®. Direct in vitrobathing of cultured mouse embryos with pentosan polysulfate sodium (PPS) at a concentration of 1 mg/mL may cause reversible limb bud abnormalities. Adequate and well-controlled studies have not been performed in pregnant women. Because animal studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.
<P>PROBLEM TO BE SOLVED: To provide a user-friendly electronic medical chart patient condition correspondence table display system promptly displaying patient information to easily obtain necessary information.  <P>SOLUTION: The patient information is previously stored. Screen display pattern information is previously stored by diagnosis names. A name of a patient is displayed on a monitor 18. The name of the patient to be examined is selected from the names of the patients displayed on the monitor 18 (step 40). The patient information corresponding to the name of the selected patient is retrieved. The diagnosis name of the retrieved patient information is acquired (step 41). A screen pattern code corresponding to the diagnosis name is acquired (step 43). The screen display pattern information corresponding to the acquired screen pattern code is retrieved (step 44). The patient information is edited on the basis of the retrieved screen display pattern information (step 45). The patient information is displayed on the monitor 18 (step 46).  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A retrospective review was conducted of data from adult patients with cancer undergoing collection of peripheral blood progenitor cells (PBPC) at a single transplant center. Mobilization of PBPC and myeloid reconstitution post transplant were compared between four groups of patients (n=196) receiving LEUKINE for mobilization and a historical control group who did not receive any mobilization treatment [progenitor cells collected by leukapheresis without mobilization (n=100)]. Sequential cohorts received LEUKINE. The cohorts differed by dose (125 or 250 mcg/m2/day), route (IV over 24 hours or SC) and use of LEUKINE post transplant. Leukaphereses were initiated for all mobilization groups after the WBC reached 10,000 cells/mm3. Leukaphereses continued until both a minimum number of mononucleated cells (MNC) were collected (6.5 or 8.0 × 108/kg body weight) and a minimum number of aphereses (5-8) were performed. Both minimum requirements varied by treatment cohort and planned conditioning regimen. If subjects failed to reach a WBC of 10,000 cells/mm3 by day 5, another cytokine was substituted for LEUKINE. 

Marked mobilization effects were seen in patients administered the higher dose of LEUKINE (250 mcg/m2) either IV (n=63) or SC (n=41). PBPCs from patients treated at the 250 mcg/m2/day dose had a significantly higher number of granulocyte-macrophage colony-forming units (CFU-GM) than those collected without mobilization. The mean value after thawing was 11.41 × 104 CFU-GM/kg for all LEUKINE-mobilized patients, compared to 0.96 × 104/kg for the non-mobilized group. A similar difference was observed in the mean number of erythrocyte burst-forming units (BFU-E) collected (23.96 × 104/kg for patients mobilized with 250 mcg/m2 doses of LEUKINE administered SC vs. 1.63 × 104/kg for non-mobilized patients).

A second retrospective review of data from patients undergoing PBPC at another single transplant center was also conducted. LEUKINE was given SC at 250 mcg/m2/day once a day (n=10) or twice a day (n=21) until completion of apheresis. Apheresis was begun on day 5 of LEUKINE administration and continued until the targeted MNC count of 9 × 108/kg or CD34+ cell count of 1 × 106/kg was reached. There was no difference in CD34+ cell count in patients receiving LEUKINE once or twice a day.
In this pre-post design pilot study participants will be recruited from self-management courses for people with rheumatic diseases. Before using the application participants will be asked to report their strengths in a written format. After using the mobile application to reflect on their strengths the participants will be interviewed about their experience of using the application and on the task of reflecting on their strengths. They will also be asked to fill out a questionnaire on perceived usefulness and user-friendliness. Before and after using the application the participants fill out questionnaires on emotions (Positive and Negative Affective Scale) and self-efficacy (The Arthritis Self-efficacy Scale). All interviews will be audio-taped and analyzed with a qualitative approach. Descriptive analysis will be applied for quantitative data.
The invention relates to the field of natural disintegrant pre-mixes which are useful for formulating solid dosage forms for oral administration of drugs, vitamins, food supplements, etc. The composition comprises a blend about 20% to about 90% by weight of Psyllium Husk and about 5% to about 60% by weight of Oat Fiber (all weight percentages being based on the dry weight of the disintegrant composition). The composition may further comprise about 1% to about 25% by weight of at least one further component selected from guar gum, Locust bean gum, gum karaya, Aegle marmelose gum, Mangifera indica gum, and a combination thereof and/or about 1% to about 20% by weight of at least one further component selected Apple Fiber, Wheat Fiber, Pea Fiber, Cellulose Powder, Agave Powder, Bamboo Fiber, and a combination thereof (all weight percentages being based on the dry weight of the disintegrant composition). The natural disintegrant composition provides super disintegrant properties to the tablet, while maintaining excellent properties of homogeneity, flowability and compressibility during the manufacture of the solid oral dosage form. Tablets made with the conventional/organic super disintegrant composition may be labelled as "natural". The composition may replace conventional super disintegrants like croscarmellose or crospovidone.
The restrictive portion of the surgery involves removing approximately 70% of the stomach (along the greater curvature) and most of the duodenum. The malabsorptive portion of the surgery reroutes a lengthy portion of the small intestine, creating two separate pathways and one common channel.The common channel is 200 cm and 100m the alimentary limb.